UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close
Already an Engineering360 user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

close
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

ASTM F2065

Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials

inactive
Buy Now
Organization: ASTM
Publication Date: 10 November 2000
Status: inactive
Page Count: 7
ICS Code (Implants for surgery, prosthetics and orthotics): 11.040.40
scope:

This practice provides a protocol for rapid, in vitro screening for alternative pathway complement activating properties of solid materials used in the fabrication of medical devices that will contact blood.

This practice is intended to evaluate the acute in vitro alternative pathway complement activating properties of solid materials intended for use in contact with blood. For this practice, "serum" is synonymous with "complement."

This practice consists of two procedural parts. Procedure A describes exposure of solid materials to a standard lot of C4-deficient guinea pig serum [C4(-)GPS], using 0.1-mL serum per 13 X 100-mm disposable glass test tubes. Sepharose2 CL-4B is used as an example of test materials. Procedure B describes assaying the exposed serum for significant functional alternative pathway complement depletion as compared to control samples. The endpoint in procedure B is lysis of rabbit RBC in buffer containing EGTA and excess Mg++.

This practice does not address function, elaboration, or depletion of individual complement components except as optional additional confirmatory information that can be acquired using human serum as the complement source. This practice does not address the use of plasma as a source of complement.

This practice is one of several developed for the assessment of the biocompatibility of materials. Practice F 748 may provide guidance for the selection of appropriate methods for testing materials for other aspects of biocompatibility. Practice F 1984 provides guidance for testing solid materials for whole complement activation in human serum, but does not discriminate between the classical or alternative pathway of activation.

2 Sepharose is a registered trademark of Pharmacia, Inc. (now GE Healthcare), Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA, U.K.

Document History

November 10, 2000
Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials
This practice provides a protocol for rapid, in vitro screening for alternative pathway complement activating properties of solid materials used in the fabrication of medical devices that will...
ASTM F2065
November 10, 2000
Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials
This practice provides a protocol for rapid, in vitro screening for alternative pathway complement activating properties of solid materials used in the fabrication of medical devices that will...
November 10, 2000
Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials
1. Scope 1.1 This practice provides a protocol for rapid, in vitro screening for alternative pathway complement activating properties of solid materials used in the fabrication of medical devices...
November 10, 2000
Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials
1. Scope 1.1 This practice provides a protocol for rapid, in vitro screening for alternative pathway complement activating properties of solid materials used in the fabrication of medical devices...

References

Advertisement